Stock data
Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc. (TOVX) reported net income of -US$23.74M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$24.05M | -US$23.74M | — |
| 2024 | — | — | -US$26.35M | -US$25.65M | — |
| 2023 | — | — | -US$21.43M | -US$18.35M | — |
| 2022 | — | — | -US$21.58M | -US$19.68M | — |
| 2021 | — | — | -US$14.27M | -US$14.27M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$3.22M | — |
| 2026-03-31 | US$0.30M | -US$2.04M | — |
| 2025-12-31 | — | -US$2.00M | — |
| 2025-09-30 | — | -US$4.36M | — |
| 2025-06-30 | — | -US$13.06M | — |
| 2025-03-31 | — | -US$4.32M | — |
| 2024-12-31 | — | -US$4.45M | — |
| 2024-09-30 | — | -US$7.73M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.